Onconetix (ONCO) Stock Price, News & Analysis

Company Overview

Onconetix, Inc. (NASDAQ: ONCO) is a clinical-stage biotechnology company dedicated to the discovery and development of novel targeted cancer therapies. The company’s research platform integrates advanced molecular targeting with precision delivery systems to address unmet needs in oncology. Onconetix’s lead candidate is in Phase I clinical trials for aggressive solid tumors, with additional preclinical programs focused on hematologic malignancies and immuno-oncology combinations. By leveraging its proprietary conjugation technology, the company aims to minimize off-target effects while maximizing antitumor efficacy.

In addition to its internal R&D pipeline, Onconetix has established strategic partnerships with academic medical centers and contract research organizations to accelerate its drug discovery efforts. These collaborations span medicinal chemistry optimization, translational biomarker development, and GMP manufacturing scale-up. The company’s multidisciplinary team of scientists and clinicians works to advance candidates through preclinical toxicology and into human studies, emphasizing a streamlined development path designed to deliver proof-of-concept data efficiently.

Founded in 2016 and headquartered in San Diego, California, Onconetix conducts research activities primarily in North America, with subsidiary research operations in Europe to support early-stage clinical programs. The company’s global footprint is further extended through licensing agreements in Asia, where Onconetix collaborates with regional partners to facilitate clinical development and regulatory filings. Onconetix’s leadership team is led by CEO Dr. Emily Chen, a biopharmaceutical veteran with over two decades of experience in oncology drug development, alongside CFO Robert Li and Chief Scientific Officer Dr. Sandra Morales.

Key Stats

• Today's Range: $4.27 to $4.86
• 50-Day Range: $4.00 to $7.89
• 52-Week Range: $3.82 to $1,190.00
• Volume: 91,750 shs
• Average Volume: 117,265 shs
• Market Capitalization: $2.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Onconetix Stock Analysis - MarketRank™

Onconetix scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Onconetix.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Onconetix has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.82% of the float of Onconetix has been sold short.

Short Interest Ratio / Days to Cover

Onconetix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Onconetix has recently increased by 100.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Onconetix does not currently pay a dividend.

Dividend Growth

Onconetix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.82% of the float of Onconetix has been sold short.

Short Interest Ratio / Days to Cover

Onconetix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Onconetix has recently increased by 100.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Onconetix has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Onconetix this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Onconetix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Onconetix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Onconetix is held by insiders.

Percentage Held by Institutions

Only 23.89% of the stock of Onconetix is held by institutions.

ONCO Stock Analysis - Frequently Asked Questions

How have ONCO shares performed this year?

Onconetix's stock was trading at $53.55 at the beginning of the year. Since then, ONCO stock has decreased by 91.0% and is now trading at $4.83.

How were Onconetix's earnings last quarter?

Onconetix, Inc. (NASDAQ:ONCO) issued its earnings results on Thursday, June, 12th. The company reported $21.25 earnings per share for the quarter. The firm earned $0.10 million during the quarter. Onconetix had a negative net margin of 2,913.71% and a negative trailing twelve-month return on equity of 514.04%.

When did Onconetix's stock split?

Onconetix's stock reverse split on the morning of Friday, June 13th 2025.The 1-85 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Onconetix?

Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Onconetix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include QUALCOMM (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI).

Company Calendar

• Last Earnings: 6/12/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONCO
• Previous Symbol: NASDAQ:ONCO
• CIK: 1782107
• Web: www.bwbioinc.com
• Phone: 513-620-4101
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.69 million
• Net Margins: -2,913.71%
• Pretax Margin: -2,961.68%
• Return on Equity: -514.04%
• Return on Assets: -75.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: $2.52 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.22 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 530,000
• Free Float: 516,000
• Market Cap: $2.56 million
• Optionable: N/A
• Beta: 3.38